Catalog No.
PAA30301
Host species
Rabbit
Isotype
IgG
Clonality
Polyclonal
Immunogen
Denosumab
Tested applications
ELISA: 1:4000-1:8000
Target
Rabbit polyclonal to Prolia.
Specificity
The product is specific for Denosumab. This antibody serves as an excellent positive control for Denosumab immunogenicity (ADA) assays.
Concentration
0.6 mg/ml
Purification
Purified by antigen affinity column.
Accession
CAS: 615258-40-7
Applications
ELISA
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.
Stability and Storage
The product can be stored for 2 - 3 weeks at 2 to 8°C or for up to 12 months at -20°C. Avoid repeated freezing and thawing cycles.
Background
Denosumab with trade name Prolia, is an FDA-approved drug for the treatment of patients with osteoporosis, treatment-induced bone loss, metastases to bone, and giant cell tumor of bone. Denosumab is a fully human monoclonal antibody that works as a RANK ligand (RANKL) inhibitor. Denosumab can bind RANKL, preventing RANKL from activating RANK, its receptor on the osteoclast surface.
RANKL Drives Bone Metastasis in Mammary Cancer: Protective Effects of Anti-Resorptive Treatments., PMID:40507804
Bisphosphonate beak without the bisphosphonate: atypical femoral fracture with denosumab., PMID:40506101
Patterns of adjuvant bone modifying agent use in patients with early-stage breast cancer in the United States., PMID:40500761
Delayed-onset hypocalcaemia and hypophosphataemia induced by iron infusion in the context of denosumab therapy., PMID:40499946
Denosumab in patients with osteogenesis imperfecta and a historical control study with alendronate., PMID:40496553
Moderate-to-severe hypercalcemia secondary to primary hyperparathyroidism refractory to conventional treatment (therapeutic management with denosumab): case report and literature review., PMID:40486005
Impact of denosumab on muscle health in older adults in long-term care., PMID:40460961
Long-term effectiveness and safety of denosumab for osteoporosis in patients with rheumatic diseases., PMID:40451270
Comparison of Type 2 Diabetes Risk in Osteoporosis Patients Treated with Denosumab or Alendronate: A Nationwide Cohort Study., PMID:40445395
Five-Year Sales Trends of Osteoporosis Medications in Korea: A Market Analysis Based on IMS Health Sales Audit Data (2018-2023)., PMID:40428763
Supra-Physiological Levels of Magnesium Counteract the Inhibitory Effect of Zoledronate on RANKL-Dependent Osteoclastogenesis., PMID:40427722
Mouse model of anti-RANKL discontinuation reveals reduced bone mass and quality through disruption of bone remodeling., PMID:40425548
Symptomatic hypocalcaemia after administration of denosumab and iron infusion in patients with normal and impaired renal function., PMID:40423532
Role of denosumab in lipid metabolism disorders: clinical significance and potential mechanisms., PMID:40418391
Evaluation of Anti-SARS-CoV-2 IgG Responses in a Clinical Study of a Biosimilar Candidate to Denosumab Using Singlicate Analysis., PMID:40408051
Denosumab treatment of giant cell tumors in the spine induces woven bone formation., PMID:40390810
Incidence of medication-related osteonecrosis of the jaw and associated antiresorptive drugs in adult Finnish population., PMID:40389539
Spinal giant cell tumour presenting as a posterior mediastinal mass., PMID:40379300
Monitoring denosumab therapy using the calcium isotope marker (CIM) technology., PMID:40374024
Management of Medication-Related Osteonecrosis of the Jaw in Multiple Myeloma Patients With Pentoxifylline and Tocopherol: Case Reports., PMID:40370694
Target tolerance improvement of the immunogenicity assay developed for analysing samples from clinical trials of RGB-14, a proposed biosimilar to Prolia/Xgeva., PMID:40368321
Impacts of Prior Anti-Osteoporosis Treatments on Sequential Denosumab Responses in BMD Changes Among Postmenopausal Osteoporosis Women in East China: Real-World Data Analysis., PMID:40357344
Denosumab as an immune modulator in HER2-negative early breast cancer: results of the window-of-opportunity D-BIOMARK clinical trial., PMID:40350430
Efficacy of denosumab in treatment of osteoporosis in patients with rheumatoid arthritis: a meta-analysis of randomized controlled trial., PMID:40335975
Assessing the Efficacy of Romosozumab in Postmenopausal Osteoporosis: An Updated Systematic Review and Meta-analysis., PMID:40323656
Calf circumference predicts changes of bone mineral density in postmenopausal osteoporotic women receiving denosumab., PMID:40323522
Surgical and radiological outcomes of giant cell tumor of the bone: prognostic value of Campanacci grading and selective use of denosumab., PMID:40317378
Rebound hypercalcaemia timing is associated with cumulative weight-based denosumab dose for central giant cell granuloma treatment in children despite a dose weaning regimen., PMID:40311887
Efficacy and safety of abaloparatide, denosumab, teriparatide, oral bisphosphonates, and intravenous bisphosphonates in the treatment of male osteoporosis: a systematic review and Bayesian network meta-analysis., PMID:40309441
[Changes in circulating levels of calcium and bone metabolism biochemical markers in patients receiving denosumab treatment]., PMID:40294926
[Update of the recommendations for the management and treatment of giant cell bone tumors, on behalf of GroupOS]., PMID:40268651
Interrogation of Structure-Activity Relationships in Charge Variants of Therapeutic IgG2s Enabled by Free-Flow Isoelectric Focusing Fractionation., PMID:40263152
[Sequential drug treatments for osteoporosis]., PMID:40241552
Navigating Stomatologic Complications Secondary to Antineoplastic Agents-A Comprehensive Review., PMID:40227621
Long-Term Denosumab Treatment in Adults with Juvenile Paget Disease., PMID:40223037
Inhibition of RANKL is critical for accurate assessment of anti-drug antibody incidence to denosumab in clinical studies., PMID:40220951
Enhancing Akkermansia growth via phytohormones: a strategy to modulate the gut-bone axis in postmenopausal osteoporosis therapy., PMID:40205438
Denosumab for treating periprosthetic osteolysis: a feasibility study., PMID:40200363
Mild antiresorptive activity of an anti-vascular endothelial growth factor A antibody and sunitinib in a rat model of bone resorption., PMID:40177629
The Effects of Denosumab Treatment on Pain and Function Beyond Bone Density in Patients With Postmenopausal Osteoporosis: A Prospective Study., PMID:40171992
Osteoporosis medication use over time in the United States and Canada., PMID:40169456
Influence of Lumbar Epidural Steroid Injection on Osteoporosis and Denosumab Treatment., PMID:40168571
Navigating skeletal wellness after breast cancer., PMID:40154015
Research Progress on the Influence of Novel Targeted Drugs for Osteoporosis on Glucose Metabolism., PMID:40149867
Impact of Zoledronic Acid on Bone Mineral Density and Trabecular Score Following Denosumab Discontinuation in Older Adults in Long-Term Care., PMID:40146262
[Combined Proximal Radius Reconstruction Following Resection for Oncological Indication]., PMID:40145589
Phytoestrogens as potential anti-osteoporosis nutraceuticals: Major sources and mechanism(s) of action., PMID:40139537
Photobiomodulation in Patients Taking Denosumab: Case Report and Literature Review., PMID:40136756
Denosumab regimens in the treatment of giant cell tumor of bone: A systematic review with meta-analysis., PMID:40124723
Sequential and Long-term Therapy for Osteoporosis., PMID:40119973
For research use only. Not for human or drug use.
